Immutep Quarterly Activities Report and Appendix 4C
Filed with ASX · · 12 pages · English
• Entered into strategic collaboration with Dr. Reddy’s for commercialisation of eftilagimod alfa (efti) in all countries outside North America, Europe, Japan, and Greater China • In January 2026, Immutep received ~A$30 million upfront payment from Dr. Reddy’s and is eligible to receive up to ~A$528 million in potential milestones, plus royalties on commercial sales of efti • Strong operational pr
Story so far
Earlier from Immutep
- Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study
- Positive Update on IMP761 Phase 1
- Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace
- TACTI-004 phase III trial enrolment continues at robust pace
- Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa
Later from Immutep
- Immutep Quarterly Activities Report Q2 FY26
- Immutep Achieves 50% Enrolment in Global TACTI-004-1L NSCLC
- Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC
- Half Yearly Report and Accounts
- Trading Halt
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep